Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
| PHAT Stock | USD 8.84 0.13 1.49% |
Slightly above 56% of Phathom Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Phathom Pharmaceuticals stock suggests that many investors are alarmed at this time. Phathom Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Phathom Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Phathom |
Net revenues of 16.4 million reported for the third quarter 2024 compared to 7.3 million in the second quarter 2024, over 120 percent sequential quarterly increaseOver 143,000 prescriptions filled for VOQUEZNA products, launch to date, a 138 percent increase since last quarterly reportCommercial access for VOQUEZNA tablets expanded, now covering over 80 percent of U.S. commercial livesManagement to host conference call today, November 7, 2024, at 830 am ET FLORHAM PARK, N.J., Nov. 07, 2024 GLOBE NE
Read at finance.yahoo.com
 |
Phathom Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Phathom Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Phathom Pharmaceuticals Fundamental Analysis
We analyze Phathom Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Phathom Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Phathom Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Phathom Pharmaceuticals is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Phathom Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Phathom Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Phathom Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Phathom Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Phathom Pharmaceuticals Related Equities
| CNTB | Connect Biopharma | 2.78 | ||||
| ENTA | Enanta Pharmaceuticals | 2.22 | ||||
| CRNX | Crinetics Pharmaceuticals | 1.39 | ||||
| FOLD | Amicus Therapeutics | 1.71 | ||||
| LGND | Ligand Pharmaceuticals | 2.26 | ||||
| DSGN | Design Therapeutics | 4.62 | ||||
| ORIC | Oric Pharmaceuticals | 5.60 | ||||
| LYEL | Lyell Immunopharma | 6.00 | ||||
| RVMD | Revolution Medicines | 6.89 | ||||
| PASG | Passage Bio | 11.88 |
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.